We use our unique microRNA-based biomarkers to personalize cancer treatment and drug development. MiraDx is creating biomarker panels to predict both toxicity (immune-related adverse events (iRAEs)) as well as response to the developing immunotherapies. Their first test predicts iRAEs to anti-PD1/PDL1 therapy across all cancer types.
So, patients with any type of cancer who are being considered for this therapy are eligible for testing. Recent data now indicates that changing estrogen levels, specifically estrogen withdrawal, can trigger cancer in women with the KRAS-variant. Knowing a woman's KRAS-variant status is an additional piece of critically important information to help direct decisions for estrogen management, as well as primary and secondary cancer screening.
So, patients with any type of cancer who are being considered for this therapy are eligible for testing. Recent data now indicates that changing estrogen levels, specifically estrogen withdrawal, can trigger cancer in women with the KRAS-variant. Knowing a woman's KRAS-variant status is an additional piece of critically important information to help direct decisions for estrogen management, as well as primary and secondary cancer screening.
Services
Improve assessment of individual patient's responses and toxicity profiles to specific therapies, to radically change the meaning of personalized medicine. Our cutting-edge genetic research discovered a new class of genetic biomarkers that can dramatically change personalized treatment. MiraDx partners with universities and pharmaceutical companies to utilize our unique genetic research to help better treat cancer.
MiraDx is committed to discovering meaningful ways to better treat cancer in patients with mutations like and including the KRAS-variant. Radiation therapy is a form of cancer treatment that is used in over 2/3 of cancer patients diagnosed every year. Although generally, radiation is a safe treatment, 5-10% of patients will experience serious side effects from treatment.
As our founders are leaders in the field of microRNA genetics, our platform of mutations are novel and not tested by others. With over 35 years of microRNA expertise behind us, we are able to narrow our focus on the most predictive and important germ-line mutations that impact microRNA function and signaling, leading to biomarker identification even in small patient numbers.
Patients with any type of cancer who are being considered for anti-PD1 or anti-PDL1 therapy are eligible for testing. This test predicts the risk of developing immune related adverse events in response to anti-PD1 or anti-PDL1 treatment. ImuDx ordering takes place by first obtaining kits from MiraDx, and then as patients are tested, filling out our online requisition for each patient before sending their kit in to MiraDx.
Reviews (3)
Ken Shu
May 21, 2021
Report
Steve Kinsey
Sep 01, 2020
Report
Cord Lambrecht
Aug 23, 2020
Report
Took a covid test almost two weeks ago. Still waiting on the results. Will update if I hear anything of if I can get through on the broken phone line.
Update: I heard back, along with others who took the test on the same day. This company is nearly two weeks behind on testing, as of Monday, May 4th. I appreciate that they're looking to help but feel that if they are unprepared they should not take on duties like this irresponsibly.
Update: I heard back, along with others who took the test on the same day. This company is nearly two weeks behind on testing, as of Monday, May 4th. I appreciate that they're looking to help but feel that if they are unprepared they should not take on duties like this irresponsibly.
